POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program on biomarkers in women with early-stage breast cancer.

TPS9657 Background: The majority of women diagnosed with breast cancer are overweight or obese, and gain weight with treatment, leading to inferior survival outcomes. The Practice-based Opportunities for Weight Reduction (POWER) investigators reported that, in an obese population with cardiovascular risk factors, a scalable remote-based weight loss intervention was equally effective to an in-person intervention (Appel NEJM 2011). We have adapted the remote intervention for breast cancer survivors. Methods: Randomized phase II single-blinded trial. Participants are women with stage 0-III breast cancer and a BMI ≥ 25 who have completed local therapy and adjuvant chemotherapy. Objectives:1.) Compare the proportion of participants who lose ≥5% of their baseline body weight after 6 and 12 months in the POWER-remote and self-directed (control) arms; 2.) Investigate the effects of weight loss on a panel of biomarkers relevant to obesity, inflammation, and breast cancer risk (insulin, IGF-1, hsCRP, IL-1, IL-6, TN...